Fennec Pharmaceuticals Inc.
Price Action
Technical Summary
EMERGING TRENDFennec Pharmaceuticals Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 90), indicating clear outperformance against the broad market. Earnings growth of 113% provides fundamental context to the price action. However, price is extended 31% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $9.45 | +16.61% | ABOVE |
| 50 SMA | $8.43 | +30.75% | ABOVE |
| 100 SMA | $7.95 | +38.53% | ABOVE |
| 150 SMA | $7.86 | +40.15% | ABOVE |
| 200 SMA | $8.07 | +36.63% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is FENC in an uptrend right now?
FENC has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is FENC overbought or oversold?
FENC's RSI (14) is 72. The stock is in overbought territory (RSI > 70), which may signal a pullback.
Is FENC outperforming the market?
FENC has a Relative Strength (RS) Rating of 90 out of 99. Yes, FENC is a market leader, outperforming 90% of all stocks over the past 12 months.
Where is FENC in its 52-week range?
FENC is trading at $11.02, which is 100% of its 52-week high ($11.04) and 100% above its 52-week low ($5.65).
How volatile is FENC?
FENC has a Beta of 1.64 and 52-week volatility of 64%. It's more volatile than the S&P 500 - expect bigger swings.